- Home
- SOPA vs RNAZ Comparison
SOPA vs RNAZ Comparison
Compare SOPA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPA
- RNAZ
- Stock Information
- Founded
- SOPA 2018
- RNAZ 2016
- Country
- SOPA Singapore
- RNAZ United States
- Employees
- SOPA N/A
- RNAZ N/A
- Industry
- SOPA EDP Services
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SOPA Technology
- RNAZ Health Care
- Exchange
- SOPA Nasdaq
- RNAZ Nasdaq
- Market Cap
- SOPA 7.3M
- RNAZ 8.7M
- IPO Year
- SOPA 2021
- RNAZ 2021
- Fundamental
- Price
- SOPA $2.16
- RNAZ $10.71
- Analyst Decision
- SOPA Strong Buy
- RNAZ Strong Buy
- Analyst Count
- SOPA 1
- RNAZ 1
- Target Price
- SOPA $18.00
- RNAZ $280.00
- AVG Volume (30 Days)
- SOPA 996.5K
- RNAZ 421.9K
- Earning Date
- SOPA 11-13-2025
- RNAZ 11-14-2025
- Dividend Yield
- SOPA N/A
- RNAZ N/A
- EPS Growth
- SOPA N/A
- RNAZ N/A
- EPS
- SOPA N/A
- RNAZ N/A
- Revenue
- SOPA $7,522,939.00
- RNAZ N/A
- Revenue This Year
- SOPA $26.32
- RNAZ N/A
- Revenue Next Year
- SOPA $13.64
- RNAZ N/A
- P/E Ratio
- SOPA N/A
- RNAZ N/A
- Revenue Growth
- SOPA 0.31
- RNAZ N/A
- 52 Week Low
- SOPA $0.64
- RNAZ $6.15
- 52 Week High
- SOPA $6.75
- RNAZ $504.97
- Technical
- Relative Strength Index (RSI)
- SOPA 45.06
- RNAZ 38.66
- Support Level
- SOPA $2.52
- RNAZ $10.90
- Resistance Level
- SOPA $3.14
- RNAZ $13.92
- Average True Range (ATR)
- SOPA 0.32
- RNAZ 0.92
- MACD
- SOPA -0.14
- RNAZ -0.48
- Stochastic Oscillator
- SOPA 4.96
- RNAZ 2.75
About SOPA Society Pass Incorporated
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.